References
- 1Gong W, Wei X, Liang Y, et al. Urban and Rural Differences of Acute Cardiovascular Disease Events: A Study from the Population-Based Real-Time Surveillance System in Zhejiang, China in 2012. PLoS One. 2016; 11(11): e0165647. DOI: 10.1371/journal.pone.0165647
- 2Fiedorowicz JG. Depression and cardiovascular disease: An update on how course of illness may influence risk. Curr Psychiatry Rep. Oct 2014; 16(10): 492. DOI: 10.1007/s11920-014-0492-6
- 3Goldstein BI, Carnethon MR, Matthews KA, et al. Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. September 8, 2015; 132(10): 965–86. DOI: 10.1161/CIR.0000000000000229
- 4De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci. Mar 2018; 20(1): 31–40. DOI: 10.31887/DCNS.2018.20.1/mdehert
- 5Kilbourne AM, Goodrich DE, Lai Z, et al. Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: The Self-Management Addressing Heart Risk Trial (SMAHRT). J Clin Psychiatry. July 2013; 74(7): e655–62. DOI: 10.4088/JCP.12m08082
- 6Weiner M, Warren L, Fiedorowicz JG. Cardiovascular morbidity and mortality in bipolar disorder. Ann Clin Psychiatry. February 2011; 23(1): 40–7.
- 7Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. June 2, 2004; 291(21): 2581–90. DOI: 10.1001/jama.291.21.2581
- 8Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. January 3, 2009; 373(9657): 31–41. DOI: 10.1016/S0140-6736(08)61764-X
- 9Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. June 2003; 60(6): 553–64. DOI: 10.1001/archpsyc.60.6.553
- 10Censo Nacional de Poblacion y Vividenda 2018 (2018).
- 11Alfaro Moreno LXG, Castrillón CC, Gil JJM, et al. Relación entre trastorno afectivo bipolar, depresión, ansiedad, estrés y valores de presión arterial en población de la Clinica San Juan de Dios, Manizales, Colombia, 2014. Archivos de Medicina (Col). 2015; 15(2): 281–290. DOI: 10.30554/archmed.15.2.1027.2015
- 12Ayerbe L, Forgnone I, Addo J, Siguero A, Gelati S, Ayis S. Hypertension risk and clinical care in patients with bipolar disorder or schizophrenia; A systematic review and meta-analysis. J Affect Disord. January 1, 2018; 225: 665–670. DOI: 10.1016/j.jad.2017.09.002
- 13Johannessen L, Strudsholm U, Foldager L, Munk-Jorgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. October 2006; 95(1–3): 13–7. DOI: 10.1016/j.jad.2006.03.027
- 14Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. December 15, 2012; 380(9859): 2197–223. DOI: 10.1016/S0140-6736(12)61689-4
- 15D’Agostino RB,
Sr. , Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation. February 12, 2008; 117(6): 743–53. DOI: 10.1161/CIRCULATIONAHA.107.699579 - 16Mendis S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. Prog Cardiovasc Dis. July–August 2010; 53(1): 10–4. DOI: 10.1016/j.pcad.2010.01.001
- 17Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: An appraisal of its benefits and limitations. Am Heart Hosp J. Spring 2007; 5(2): 91–6. DOI: 10.1111/j.1541-9215.2007.06350.x
- 18D’Agostino RB,
Sr. , Grundy S, Sullivan LM, Wilson P, Group CHDRP. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA. July 11, 2001; 286(2): 180–7. DOI: 10.1001/jama.286.2.180 - 19Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. October 2013; 46(15): 1323–38. DOI: 10.1016/j.clinbiochem.2013.06.012
- 20Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. December 2016; 4(1): 27. DOI: 10.1186/s40345-016-0068-y
- 21Visser HM, Van Der Mast RC. Bipolar disorder, antidepressants and induction of hypomania or mania. A systematic review. World J Biol Psychiatry. 2005; 6(4): 231–41. DOI: 10.1080/15622970510029885
- 22Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. June 2015; 14(2): 119–36. DOI: 10.1002/wps.20204
- 23Penninx B, Lange SMM. Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications. Dialogues Clin Neurosci. March 2018; 20(1): 63–73. DOI: 10.31887/DCNS.2018.20.1/bpenninx
- 24Dargel AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder: A meta-analysis. J Clin Psychiatry. February 2015; 76(2): 142–50. DOI: 10.4088/JCP.14r09007
- 25Marshe VS, Pira S, Mantere O, et al. C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. October 3, 2017; 79(Pt B): 442–451. DOI: 10.1016/j.pnpbp.2017.07.026
- 26Stein DJ, Aguilar-Gaxiola S, Alonso J, et al. Associations between mental disorders and subsequent onset of hypertension. Gen Hosp Psychiatry. March–April 2014; 36(2): 142–9. DOI: 10.1016/j.genhosppsych.2013.11.002
- 27Camacho PA, Gomez-Arbelaez D, Molina DI, et al. Social disparities explain differences in hypertension prevalence, detection and control in Colombia. J Hypertens. December 2016; 34(12): 2344–2352. DOI: 10.1097/HJH.0000000000001115
- 28Rosengren A, Smyth A, Rangarajan S, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: The Prospective Urban Rural Epidemiologic (PURE) study. Lancet Glob Health. June 2019; 7(6): e748–e760. DOI: 10.1016/S2214-109X(19)30045-2
- 29Querales-Carrasquel MI, Rojas-Pacheco SA, Silva E, et al.
Cardiovascular risk factors in urban and rural communities from Tinaquillo, Venezuela . Rev Salud Publica (Bogota). March–April 2017; 19(2): 188–193. Factores de riesgo cardiovascular en comunidades urbana y rural. Tinaquillo, Venezuela. DOI: 10.15446/rsap.v19n2.41332 - 30Yan R, Li W, Yin L, Wang Y, Bo J, Investigators PU-C. Cardiovascular Diseases and Risk-Factor Burden in Urban and Rural Communities in High-, Middle-, and Low-Income Regions of China: A Large Community-Based Epidemiological Study. J Am Heart Assoc. February 6, 2017; 6(2). DOI: 10.1161/JAHA.116.004445
- 31Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. August 28, 2014; 371(9): 818–27. DOI: 10.1056/NEJMoa1311890
- 32Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S, Group PI-W. The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. July 2009; 158(1): 1–7 e1. DOI: 10.1016/j.ahj.2009.04.019
- 33Lucaroni F, Cicciarella Modica D, Macino M, et al. Can risk be predicted? An umbrella systematic review of current risk prediction models for cardiovascular diseases, diabetes and hypertension. BMJ Open. December 19, 2019; 9(12): e030234. DOI: 10.1136/bmjopen-2019-030234